Safety trials are underway for a Cambridge-led vaccine that could be used as a booster targeting COVID-19 virus variants and relatives that threaten future coronavirus pandemics. The first volunteer is expected to receive the vaccine today at the NIHR Southampton Clinical Research Facility.…
Read More »
Safety trials are underway for a Cambridge-led vaccine that could be used as a booster targeting COVID-19 virus variants and relatives that threaten future coronavirus pandemics. The first volunteer is expected to receive the vaccine today at the NIHR Southampton Clinical Research Facility.…
You might be interested in
Older people are likely to be vaccinated regardless of party affiliation. New research from the University of Georgia suggests age and…
SARS-CoV-2 infection can trigger the production of immune molecules that damage cells lining blood vessels in the brain, causing platelets…
The FINANCIAL — COVID-19 was the third leading cause of death in the United States between March 2020 and October…
In the UK, there were 346 deaths involving COVID-19 registered in the week ending 24 June 2022, an increase from…

The FINANCIAL -- A new large-scale study shows that a quarter of the UK adult population screens positive for a potential injection phobia, University of Oxford notes.…
You might be interested in
AUGUSTA, GA: A Rockdale County, Ga., nurse practitioner has been sentenced to federal prison and ordered to pay more than…
The FINANCIAL — Parkinson’s is a progressive neurological condition, which affects around 145,000 people in the UK. Symptoms start to appear…
The FINANCIAL — A study estimating the environmental impact of 57,000 food products in the UK and Ireland has been…
In 2017, Ninja Theory, advised by Cambridge academic Professor Paul Fletcher, took the gaming world by storm with Hellblade, which…